Press "Enter" to skip to content

AstraZeneca’s Imfinzi shows sustained benefit in lung cancer study – Reuters

admin 0
  1. AstraZeneca’s Imfinzi shows sustained benefit in lung cancer study  Reuters
  2. AstraZeneca’s Checkpoint Inhibitor Imfinzi Helps Overall Survival in Lung Cancer  BioSpace
  3. Durvalumab plus chemotherapy, without tremelimumab, extends OS in small cell lung cancer  Healio
  4. Durable OS benefit boosts Imfinzi in lung cancer segment  The Pharma Letter
  5. AZ’s immunotherapy combo fails in phase 3 lung cancer trial –  pharmaphorum
  6. View Full Coverage on Google News

“lung cancer” – Google News

(Visited 1 times, 1 visits today)

Leave a Reply

Your email address will not be published. Required fields are marked *